User:Mr. Ibrahem/Fidaxomicin

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Fidaxomicin
Clinical data
Trade namesDificid, Dificlir
Other namesClostomicin B1, lipiarmicin, lipiarmycin, lipiarmycin A3, OPT-80, PAR 01, PAR-101, tiacumicin B
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B1
Routes of
administration		By mouth
Drug classMacrocyclic[1]
Legal status
Legal status
Pharmacokinetic data
BioavailabilityMinimal systemic absorption[3]
Elimination half-life11.7 ± 4.80 hours[3]
ExcretionUrine (<1%), faeces (92%)[3]
Identifiers
  • 3-(((6-Deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-β-D-mannopyranosyl)oxy)-methyl)-12(R)-[(6-deoxy-5-C-methyl-4-O-(2-methyl-1-oxopropyl)-β-D-lyxo-hexopyranosyl)oxy]-11(S)-ethyl-8(S)-hydroxy-18(S)-(1(R)-hydroxyethyl)-9,13,15-trimethyloxacyclooctadeca-3,5,9,13,15-pentaene-2-one
Chemical and physical data
FormulaC52H74Cl2O18
Molar mass1058.05 g·mol−1
3D model (JSmol)
  • CC[C@H]1/C=C(/[C@H](C/C=C/C=C(/C(=O)O[C@@H](C/C=C(/C=C(/[C@@H]1O[C@H]2[C@H]([C@H]([C@@H](C(O2)(C)C)OC(=O)C(C)C)O)O)\C)\C)[C@@H](C)O)\CO[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)\C
  • InChI=1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3/b16-15+,25-19+,26-22+,27-21+,31-17+/t28-,29-,30+,33+,34+,40-,41+,42+,43+,44-,45+,46+,50-,51-/m1/s1 ☒N
  • Key:ZVGNESXIJDCBKN-UUEYKCAUSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Fidaxomicin, sold under the brand name Dificid among others, is an antibiotic used to treat Clostridioides difficile diarrhea.[1] Evidence for use in severe disease is limited and in such cases vancomycin is preferred.[1][5] It is taken by mouth.[1]

Common side effects include nausea and constipation.[4] Other side effects may include gastrointestinal bleeding, abdominal pain, allergic reaction, and liver problems.[6] Safety in pregnancy and breastfeeding is unclear.[1] It is a macrocyclic which works by blocking bacterial RNA polymerase.[1][4]

Fidaxomicin was approved for medical use in the United States and Europe in 2011.[5][4] In the United Kingdom a course of treatment costs the NHS about £1350 as of 2021.[1] In the United States this amount costs about 4,150 USD.[7] It is made from the actinomycete Dactylosporangium aurantiacum.[6]

References[edit]

  1. ^ a b c d e f g h i BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 607. ISBN 978-0857114105.
  2. ^ "Dificlir EPAR". European Medicines Agency (EMA). Archived from the original on 28 January 2021. Retrieved 18 January 2021.
  3. ^ a b c "Dificid" (PDF). TGA eBusiness Services. Specialised Therapeutics Australia Pty Ltd. 23 April 2013. Archived from the original on 19 January 2021. Retrieved 31 March 2014.
  4. ^ a b c d "Dificlir". Archived from the original on 28 January 2021. Retrieved 10 December 2021.
  5. ^ a b "Fidaxomicin Monograph for Professionals". Drugs.com. Archived from the original on 28 February 2020. Retrieved 10 December 2021.
  6. ^ a b "Dificid- fidaxomicin tablet, film coated Dificid- fidaxomicin granule, for suspension". DailyMed. 18 February 2020. Archived from the original on 7 August 2020. Retrieved 26 March 2020.
  7. ^ "Fidaxomicin Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 29 October 2016. Retrieved 10 December 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Fidaxomicin&oldid=1168048708"